Researchers at Stanford University's Curtis Laboratory have used gene expression to categorize the sensitivity and resistance of anthracycline chemotherapy in breast cancer patients with utmost precision.
Stanford researchers have formulated a statistical model to determine the risk of breast cancer recurrence with unprecedented accuracy in women 5 – 20 years after initial diagnosis.